Extended indication Familial chylomicronemia syndrome
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Olezarsen
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Unknown
Extended indication Familial chylomicronemia syndrome
Manufacturer Ionis
Mechanism of action Unknown
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks Olezarsen is a next-generation, N-acetylgalactosamine (GalNAc)–conjugated, antisense oligonucleotide designed to inhibit APOC3–encoded apolipoprotein C-III protein production.

Registration

Registration route Unknown
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date 2024
Expected Registration 2025
Orphan drug Unknown
Registration phase Clinical trials
Additional remarks NCT04568434

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Additional remarks De effectiviteit lijkt gelijk aan volanesorsen, wat een 70% reductie in triglyceriden impliceert. Olezarsan heeft hoogstwaarschijnlijk niet de bijwerking thrombocytopenie. De fase 3 studie is in oktober 2023 afgerond, de resultaten moeten nog gepubliceerd worden.

Expected patient volume per year

Patient volume 18 - 180

Market share is generally not included unless otherwise stated.

References Orphanet
Additional remarks Familiale chylomicronemie-syndroom (FCS) heeft een geschatte prevalentie van 1:100.000 en 1: 1000.000

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information